LORELEI
LORELEI BIG 3-13 Share This Post A phase II, randomised, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with
TRANSBIG
TRANSBIG was an EU-funded consortium coordinated by the Breast International Group to promote collaboration in translational breast cancer research.
TRANSBIG was an EU-funded consortium coordinated by the Breast International Group (BIG) to promote collaboration in translational breast cancer research. TRANSBIG’s main focus was an international clinical trial known as MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy), which is sponsored by the European Organisation for the Research and Treatment of Cancer (EORTC) (www.eortc.org) and enrolled more than 6693 women in 9 European countries.
TRANSBIG’s overall aim was to individualise treatment by rapidly “translating” the latest discoveries in cancer biology made by laboratory scientists into tools that doctors can use to help make decisions about the way to treat patients.
This is because a refinement in prognosis allows for better prediction of the outcome of treatment and can thereby reduce the proportion of women receiving chemotherapy. This would simultaneously avoid unnecessary exposure to toxicity and harmful long-term side effects. The cost of cancer care would decrease, as would the burden on European health care systems.
TRANSBIG’s goal was achieved through the MINDACT clinical trial, which showed that a 70-gene signature, commercially known as MammaPrint®, when used in addition to common clinical-pathological criteria, could identify patients who could be spared adjuvant chemotherapy.
TRANSBIG ran a major international clinical trial called MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy) to test a 70-gene tool (MammaPrint®) to identify which women needed chemotherapy after surgery and which did not. More information can be found here.
39 partners in 21 countries include the European and Latin American leaders in cancer treatment, genomics, microarray technology, proteomics, bioinformatics and biostatistics. Other critical elements in the fight against breast cancer are integrated into the TRANSBIG consortium as well: a patient advocacy network and a federation of cancer societies.
Breast International Group (BIG-aisbl), Brussels | International (Coordinator) |
Institut Jules Bordet / Jules Bordet Instituut, Brussels | Belguim |
The Netherlands Cancer Institute, Amsterdam | Netherlands |
Istituto Europeo di Oncologia – European Institute of Oncology | Italy |
Karolinska Institute & Hospital, Stockholm | Sweden |
Southwest Wales Cancer Institute, Swansea | UK |
The European Organization for the Research and Treatment of Cancer (EORTC), Brussels | International |
University of Glasgow, Glasgow | UK |
Vienna General Hospital | Austria |
Chilean Cooperative Group for Oncologic Research (GOCCHI) | Chile |
The Bank of Cyprus Oncology Centre, Nicosia | Cyprus |
Dept of Oncology of the 1st Faculty of Medicine Charles University and General Teaching Hospital, Prague | Czech Republic |
Rigshopitalet, Copenhagen | Denmark |
Institut Gustave Roussy, Villejuif | France |
West German Study Group / Frauenklinik der Heinrich-Heine- Universitaet Duesseldorf | Germany |
Universitaetsfrauenklinik – Frankfurt | Germany |
Dept. of OB/GYN, Technical University of Munich | Germany |
Universitaetsklinikum Eppendorf Hamburg | Germany |
National and Kapodistrian University of Athens | Greece |
St Vincent’s Hospital, Dublin | Ireland |
Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) | Italy |
Centre Hospitalier de Luxembourg | Luxembourg |
University Maastricht / GROW | Netherlands |
Dept of Oncology & Radiotherapy, Medical University of Gdansk, Gdansk | Poland |
Portuguese Institute of Oncology, Porto Centre, Porto | Portugal |
N. N. Blokhin Cancer Research Centre, Moscow | Russia |
Institute of Oncology Ljubljana | Slovenia |
Institute of Oncology of Southern Switzerland | Switzerland |
Marmara University Hospital, Istanbul | Turkey |
Federation of European Cancer Societies | International |
Europa Donna | International |
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP) | Portugal |
International Institute for Drug Development | België |
GSF – Research Centre for Environment and Health | Germany |
Agendia | Netherlands |
Vall d’Hebron University Hospital | Spain |
Grupo Espanol de Estudio y Tratamiento deTumores Solidos | Spain |
Swiss Institute of Bioinformatics | Switzerland |
The Chancellor, Masters and Scholars of the University of Oxford | United Kingdom |
Start date: 01/03/04
End date: 28/02/11
The TRANSBIG project received funding from the European Union’s European Commission’s Framework Programme VI under grant agreement number 503426.
LORELEI BIG 3-13 Share This Post A phase II, randomised, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with
Alexandra / IMpassion030 BIG 16-05 Share This Post A phase III, multicenter, randomised, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based
Donaties van €40 of meer per jaar komen in aanmerking voor een belastingvermindering van 45%. Dit betekent dat je donatie van €40 je slechts €22 kost.
The Breast International Group is proud to adhereto the Code of Ethics of the VEF-AERF
Medegefinancierd door de Europese Unie in het kader van een operationele subsidie van het EU4Health-programma van de Europese Unie, onder subsidieovereenkomst nr. 101124555. De hier geuite ideeën en meningen komen echter uitsluitend voor rekening van de auteur(s) en geven niet noodzakelijkerwijs die van de Europese Unie of het Europese Uitvoerende Agentschap Gezondheid en digitaal beleid (HADEA) weer. Noch de Europese Unie, noch het HADEA kan ervoor aansprakelijk worden gesteld.